Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mondobiotech Holding AG Basel (RLFTF) Message Board

$RLFTF DD (opinion) From “Francesco” on Ya-hoo

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 653
(Total Views: 299)
Posted On: 01/21/2021 1:49:12 PM
Avatar
Posted By: mc67
Re: mc67 #321
$RLFTF DD (opinion) From “Francesco” on Ya-hoo board, and helps understand context of today’s PR:

“Explanation for people who think the PR is negative and already start to think about dilution. Read following points:

I can not find anything bad in this PR.

1. GEM fully invested in RLF
2. GEM ready to buy shares worth 50 mio CHF
3. Relief has full power to decide when and how much they want to
4. GEM has to pay a median price and not 0.01 as before
5. If the SP goes north direction Uplisting/Nasdaq etc. 50 mio. CHF wont be a big amount of shares.

This is just a few positive points picked from the PR”

---

“Proceeds from the SSF drawdowns will be used to produce commercial quantities of RLF-100TM (aviptadil) and acquire additional assets to expand and diversify Relief's drug pipeline.”



$RLFTF Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

GENEVA, SWITZERLAND / ACCESSWIRE / January 21, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF)

("Relief" or the "Company" , a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced that it has signed a binding agreement with the Company's main shareholder GEM Global Yield LLC SCS ("GEM" for the implementation of a new Share Subscription Facility ("SSF" in the amount of up to CHF 50 million.

GEM is Relief's longest standing shareholder, dating back to their initial investment in 2015, and currently owns over 1.3 billion shares of Relief common stock.

Read More: https://investorshangout.com/post/newpost/938...z6kD3r8sUN


(1)
(0)




Mondobiotech Holding AG Basel (RLFTF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


$MJ




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us